| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d21cbff64022f95c237c0bd3ec8656ca
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fcc8cdf3335d54c2f8704a78e32d901a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d9f4001c84b41f166635568e07d557b3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4aa176af2fb497ddaae0594ec45f9bc1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ae277a541d7b946ff059be08a5eab853 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D307-79
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D307-79 |
| filingDate |
2018-07-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2020-04-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7e4fb3e06d703e6132918d095150ade3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_45ebd551e98cc897b0dd02ef19c733ea
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b47469f81d24e059c7f29c0bacd8522f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e09db536886b3a7ade229e0978d7207e |
| publicationDate |
2020-04-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-10633363-B2 |
| titleOfInvention |
EPAC1 activators as HIV latency reversal agents (LRA) |
| abstract |
The invention relates generally to novel EPAC1 activators, such as Formula I and the preparation thereof as well as the use of EPAC1 activators as human immunodeficiency virus (HIV) latency reversal agents (LRAs). |
| priorityDate |
2017-07-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |